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THE USE OF TANDEM MASS SPECTROMETRY IN
NEWBORN SCREENING: AUSTRALIA’S EXPERIENCE
AND ITS IMPLICATIONS FOR UNITED STATES POLICY
Lauren E. Fisher†
Abstract: In recent years, the United States has drastically increased the number of
disorders screened through its newborn screening programs. This increase is made
possible by the adoption of new a technology, the tandem mass spectrometer (“MS/MS”),
which allows screening of up to thirty disorders from a single drop of a newborn’s blood.
However, such rapid expansion of screening raises concerns regarding the purpose of the
screening, as well as the current practices in place for obtaining informed consent.
Similar expansion in Australia provides a model of one approach to address these
difficult questions. As the first country to begin using MS/MS for newborn screening,
the Australian experience sheds light on the implications surrounding such expansion, as
well as one method for resolving these issues. However, close analysis reveals that the
Australian method for expanding screening would cause dissonance within the U.S. legal
system, specifically with regard to informed consent. Therefore, the American states
need to re-evaluate the implications of this screening in order to assess whether or not
such vast expansion is a good idea. Policy-makers must use caution prior to
incorporating any new disorders into newborn screening in order to protect the rights of
one of the most vulnerable citizens in our society – the newborn baby.

I.

INTRODUCTION

Newborn screening is the most common type of genetic testing
practiced in the United States today.1 These programs are responsible for
collection of blood samples, screening, and follow-up for approximately four
million births each year.2 In the U.S., newborn screening is both run and
financed by the states.3 State policy-makers also determine when to screen

†
The author would like to thank Professor Anna Mastroianni for her guidance and assistance in
writing this comment. I truly appreciate your comments. I would also like to thank Professor Kate
Batuello for her assistance with research. My editors, Rebecca Jacobs, Katherine Van Maren and Alyssa
Vegter, also deserve my thanks for their insightful comments, attention to detail, and patience throughout
the entire process. Finally, I must thank my husband Erik for his support through the process of writing
this comment, and my son Andrew for being the true inspiration behind the topic.
1
NORTH CAROLINA CENTER FOR GENOMICS AND PUBLIC HEALTH, GENETIC TESTING, available at
http://www.sph.unc.edu/nccgph/phgenetics/testing.htm (last visited Oct. 30, 2005).
2
See Leah Oliver, Newborn Genetic Screening, Genetics Brief Issue No. X: National Conference of
State Legislatures (2002); U.S. Department of Health and Human Services, 1998 National Newborn
Screening Report 16 (2001) [hereinafter National NBS Report].
3
See Linda L. McCabe et al., Newborn Screening: Rationale for a Comprehensive Fully Integrated
Public Health System, 77 MOLECULAR GENETICS & METABOLISM 267, 269 (2002).

138

PACIFIC RIM LAW & POLICY JOURNAL

VOL. 15 NO. 1

newborns, as well as the types of disorders to include within their screening
panel.4
One of the more difficult tasks facing states is deciding which
disorders to incorporate in the screening panel. A number of governmental
and nongovernmental advisory committees developed lists of criteria to
allow states to make these decisions in a deliberate and uniform fashion.5
However, the degree to which the states rely upon these criteria differs,
creating disparity in the number and type of disorders screened among the
various states.6 As a result, “which side of a state border an infant is born on
can make a life-or-death difference.”7
New technology now allows states to screen for more disorders from a
single drop of blood.8 More than forty states are already utilizing this new
technology – the tandem mass spectrometer (“MS/MS”).9 The number of
disorders included within many states’ screening panels has significantly
increased due to the adoption of MS/MS.10 This increase has led to criticism
surrounding the inadequacies of MS/MS,11 focusing on the lack of controlled
studies regarding treatment, as well as a lack of accurate diagnoses for the
disorders now included in screening.12 The question currently facing policy-

4

The term “screening panel” refers to the panel of disorders screened for in any particular state.
Including a disorder within the screening panel places a duty upon the state to have the necessary follow-up
care in place in the event that a child receives a positive test result. See id.
5
See McCabe et al., supra note 3, at 269.
6
According to the National Newborn Screening and Genetics Resource Center, states currently
screen for anywhere from 4 to more than 30 disorders. See National Newborn Screening and Genetics
Resource Center, U.S. NATIONAL SCREENING REPORT (last updated Sept. 22, 2005), available at
http://genes-r-us.uthscsa.edu/nbsdisorders.pdf (last visited Oct. 1, 2005) [hereinafter U.S. NATIONAL
SCREENING REPORT].
7
Susan Brink, Rare But Deadly, U.S. NEWS & WORLD REP., May 30, 2005, available at
www.usnews.com/usnews/health/articles/050530/30child.htm (last visited Oct. 1, 2005).
8
See McCabe et al., supra note 3, at 270.
9
See U.S. National Screening Report, supra note 6.
10
In 1998, the National NBS and Genetics Resource Center reported that the range of disorders
included in state newborn screening programs was 4 to 8. Their most recent report indicates that some
states are now testing for well over 30 disorders, primarily through MS/MS. See id.
11
See Susan E. Waisbren et al., Effect of Expanded Newborn Screening for Biochemical Genetic
Disorders on Child Oucomes and Parental Stress, 290 JAMA 2564, 2565 (2003) (the “expansion of
mandatory screening … has proceeded despite concerns”).
12
See Bridget Wilcken et al., Screening Newborns for Inborn Errors of Metabolism by Tandem
Mass Spectrometry, 348 NEW ENG. J. MED. 2304, 2304, 2311 (2003) (discussing how use of MS/MS for
newborn screening results in identifying patients as having a disorder when if fact they have only a mild, or
perhaps benign form that will never result in symptoms. It is not currently possible to determine which of
the patients were indeed at risk, and whether treatment decreases decompensation or death after diagnosis
because “formal studies are lacking.”); see also M. J. Thomason et al., A Systematic Review of Evidence for
the Appropriateness of Neonatal Screening Programmes for Inborn Errors of Metabolism, 20 J. PUB.
HEALTH & MED. 331 (1998).
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makers is what, if anything, should be done in response to the rapid increase
of screening occurring throughout the United States.
Australian newborn screening programs have used MS/MS since
1998.13 Their experience has shown that the technology detects more
newborns with genetic variances potentially connected to inborn errors of
metabolism than were detected under previous screening methods.14
However, the program also revealed that scientists do not know enough
about many of these disorders to accurately predict whether a child with a
positive result will actually suffer from that disorder.15 This lack of
knowledge prevented some of the disorders from meeting the criteria used to
determine which disorders to include in the Australian states’ screening
panels.16 To address this issue, the Australian advisory committee
responsible for setting these criteria17 altered some of the language of their
policy recommendations to justify screening for these new disorders within
the Australian states.18
While a simple change in the language of the criteria for screening
worked in Australia, a similar change in the United States would violate
well-established legal principles, such as personal autonomy and informed
consent. Therefore, the American states should examine the rapid addition
of disorders to their screening panels by looking at the results of the
Australian report.
This Comment argues that the United States should proceed with
caution in expansion of its newborn screening programs. Part II analyzes the
history of screening in the United States, as well as the criteria traditionally
relied upon by state legislators in determining which disorders to include in
screening. Part III briefly describes MS/MS, as well as the potential benefits
it offers to newborn screening programs. Part IV evaluates the Australian
experience utilizing MS/MS, and the implications of the results of that
13

See Wilcken et al., supra note 12, at 2305.
Id.
15
Id.
16
Human Genetics Society of Australia (“HGSA”) Policy Statement 1999, HGSA-Royal
Australasian College of Physicians (“RACP”) Newborn Screening Joint Subcommittee; Newborn BloodSpot Screening (1999) (copy on file with the Journal) [hereinafter HGSA Policy Statement 1999].
17
Within Australia, the HGSA and RACP form a joint subcommittee to draft policy statements on
issues such as newborn screening. The individual states rely upon these statements when drafting their
policies. The criteria developed by the HGSA-RACP for newborn screening assist states in determining
which disorders to include in a screening panel. HGSA Policy Statement for Developing New Policies
(Sept. 2000), available at http://www.hgsa.com.au/ (last visited Oct. 1, 2005).
18
HGSA Policy Statement 2004, HGSA-RACP Newborn Screening Joint Subcommittee; Newborn
Blood-Spot Screening (March 18, 2004), available at http://www.hgsa.com.au/Word/HGSApolicy
StatementNewbornScreening0204-18.03.04.doc (last visited Oct. 1, 2005) [hereinafter HGSA Policy
Statement 2004].
14
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program. This section includes a discussion on medium-chain acyl-CoA
dehydrogenase deficiency (“MCADD”), focusing on the over-detection of
this disorder through MS/MS screening. Part V suggests that because some
of the disorders do not meet the criteria required to include them in a
screening panel, states should progress with caution prior to the
incorporation of more disorders into these panels. This section also includes
an evaluation of how Australia’s criteria changed to allow for the addition of
these disorders. This Comment concludes with a discussion on how
informed consent may prohibit the states from making similar changes to
their screening policies. State policy-makers should examine this informed
consent issue and re-evaluate their programs before deciding to expand the
number of disorders screened. Such analysis will lead them in the future to
employ a more cautious approach prior to expanding screening.
II.

NEWBORN SCREENING WITHIN THE UNITED STATES MINIMIZES A
NEWBORN’S RISK OF MULTIPLE DISORDERS

Newborn screening programs within the United States have evolved to
the point where they now successfully minimize a newborn’s risk of
developing a number of inborn errors of metabolism. All fifty states and the
District of Columbia currently have legislation in place to standardize
newborn screening.19 This legislation typically delegates authority to the
state public health department, which oversees the implementation of the
program.20 However, this type of screening has not always been available,
and is in fact a fairly recent development in healthcare dating back only to
the 1960s.21
A.

The United States’ Newborn Screening Programs Have Developed to
Benefit the Newborn

In response to the initial test developed to screen for phenylketonuria
(“PKU”), the United States has implemented screening programs designed
to benefit the health of all newborns. In 1961, microbiologist Robert
19
See Bradford L. Therrell, Jr., U.S. Newborn Screening Policy Dilemmas for the Twenty-first
Century, 74 MOLECULAR GENETICS AND METABOLISM, 64, 67 (2001). For a list of state legislation see
Alissa Johnson, Newborn Genetic and Metabolic Disease Screening, NATIONAL COUNCIL OF STATE
LEGISLATURES (2005), at http://www.ncsl.org/programs/health/genetics/newborn.htm (last visited Oct. 1,
2005).
20
See Ellen Wright Clayton, Screening and Treatment of Newborns, 29 HOUS. L. REV. 85, 99
(1992).
21
See U.S. GEN. ACCOUNTING OFFICE, REPORT TO CONGRESSIONAL REQUESTERS, Newborn
Screening: Characteristics of State Programs, 4 (2003), available at http://www.gao.gov/new.items
/d03449.pdf [hereinafter GAO Report] (last visited Oct. 1, 2005).
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Guthrie22 invented an inexpensive and simple blood test to screen for the
presence of PKU in newborns.23 PKU occurs when a child has a defect in an
enzyme necessary to break down an amino acid present in most foods.24
Without this enzyme, the amino acid collects within the child’s blood
causing severe mental retardation.25 However, with proper treatment
consisting of a special diet containing little to no phenylalanine, a child can
avoid most, if not all, of the effects of this disease.26
After watching the effects of PKU on his niece, Guthrie became
determined to create a test usable for mass, population-based screening.27
The result of his work was a simple test in which healthcare workers collect
a small drop of the newborn’s blood on filter paper and then analyze it for
the presence of a genetic marker indicating whether the child in question has
PKU.28 Guthrie achieved his objective through this test and opened the door
for mass screening of PKU in newborns. He then began to promote the
passage of state laws mandating PKU screening for all newborns.29
Initially, the medical community resisted accepting PKU testing on
newborns.30 Scientists estimate this disorder has an incidence in the United
States, Britain, and most of Western Europe between one in 11,000 to 15,000
births,31 and the rarity caused hesitation in mandating such wide-spread
screening.32 However, Guthrie, along with the National Association for
Retarded Citizens, exerted pressure upon the states and eventually succeeded
in persuading Massachusetts to institute a large-scale pilot program utilizing
22
Robert Guthrie was a research scientist at Roswell Park Cancer Institute in Buffalo, New York, as
well as a faculty member at the University of Buffalo School of Medicine and Biomedical Sciences at the
time of this discovery. He later became a professor emeritus of pediatrics and microbiology at the
University of Buffalo. Throughout his life, he was also a surgeon with the National Institute of Health and
a professor and chair of the Department of Bacteriology and Immunology at the University of Kansas. He
retired in 1986 and died in 1995 in Seattle, Washington. Obituaries: Robert Guthrie, Professor; Developer
of PKU Test, U. BUFFALO REP., Aug. 31, 1995, available at http://www.buffalo.edu/reporter
/vol27/vol27n01/n14.html (last visited Oct. 1, 2005).
23
See Robert Guthrie, Blood Screening for Phenylketonuria, 178 JAMA 863 (1961); Robert Guthrie
& Ada Susi, A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of
Newborn Infants, 32 PEDIATRICS 338 (1963).
24
See Diane B. Paul, The Politics of Heredity: Essays on Eugenics, Biomedicine, and the NatureNurture Debate 173 (1998).
25
See Donal H. Chace & Theodore A. Kalas, A Biochemical Perspective on the Use of Tandem
Mass Spectrometry for Newborn Screening and Clinical Testing, 38 CLINICAL BIOCHEMISTRY 296 (2005).
26
See PAUL, supra note 24.
27
See Therrell, supra note 19.
28
See GAO Report, supra note 21, at 14-15 (2003).
29
See Harvy L. Levy & Simone Albers, Genetic Screening of Newborns, 200.01 ANN. REV.
GENOMICS HUM. GENETICS 139, 140 (2000); L.B. Andrews, State Laws and Regulations Governing
Newborn Screening, 1985 CHICAGO: AM. BAR FOUND. 167 (1985).
30
See Therrell, supra note 19.
31
See PAUL, supra note 24.
32
Id.
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the test on newborns.33 Finally, in 1963, Massachusetts adopted mandatory
testing for PKU on all newborns.34 By the late 1960s, almost every state had
mandated PKU testing on all newborns,35 and by 1975, Guthrie’s test was
mandatory in 43 states,36 covering an estimated 90% of all newborns born in
the United States.37
The widespread acceptance of PKU testing in the United States was
not an indication that the test was flawless. In fact, much remained
unknown about the disease, thus decreasing the reliability of the initial
tests.38 Specifically, many questions remained regarding the disease’s
diagnosis.39 In 1970, a survey indicated that the false-positive rate (those
receiving a positive test result that did not actually have the disease) was
abnormally high;40 for every infant identified who actually had the disease,
an estimated nineteen others received false identification from the test.41
More troubling was the fact that these false diagnoses were not harmless.42
The severely restricted diet used to treat children with a PKU diagnosis
ironically caused mental retardation, the condition it was designed to
prevent, in some of the children who falsely tested positive.43 In 1975, the
National Research Council Committee on Inborn Errors of Metabolism
issued a statement in which they admitted that “screening was started,
frequently under mandatory laws, when questions regarding diagnosis,
prognosis, and optimal management were unanswered.”44 Eventually
scientists learned enough about the disorder to reduce the false positive rate
to an acceptable level.45 However, states could have avoided this problem
had the test not been so rapidly adopted.46

33
See American Academy of Pediatrics, Serving the Family from Birth to the Medical Home, 106
PEDIATRICS 389, 389-390 (2000) [hereinafter AAP]; PAUL, supra note 24, at 174.
34
PAUL, supra note 24, at 173.
35
Levy & Albers, supra note 29, at 140.
36
See AAP, supra note 33.
37
NATIONAL RESEARCH COUNCIL COMMITTEE FOR THE STUDY OF INBORN ERRORS OF METABOLISM,
GENETIC SCREENING: PROGRAMS, PRINCIPLES, AND RESEARCH, 23 (National Academy of Sciences:
Washington, D.C. 1975).
38
Id. at 28.
39
See PAUL, supra note 24, at 177.
40
Id.
41
Id.
42
See Clayton, supra note 20, at 106; see also Gina Kolata, Panel to Advise Testing Babies for 29
Diseases, N.Y. TIMES, February 21, 2005.
43
See Clayton, supra note 20, at 105; Kolata, supra note 42.
44
See Therrell, supra note 19, at 69-70 (citing National Research Council Committee for the Study
of Inborn Errors of Metabolism, Genetic Screening: Programs, Principles, and Research 32 (1975)).
45
See Clayton, supra note 20, at 106.
46
See id.; Kolata, supra note 42.
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Despite its initial problems, the medical community regards the PKU
test as a gold standard for population based screening.47 Slowly, states
began to look at other diseases also appropriate for testing.48 As the states
widened the scope of their screening, questions arose about how to
determine which disorders should be included within a screening panel.
Different advisory committees came forward with criteria for determining
whether the screening panel should include a particular disorder. These
criteria provide structure to the programs49 and have greatly impacted
newborn screening programs in the United States.50
B.

The Criteria Developed in the United States to Determine Which
Disorders to Include in a Screening Panel Are Necessary to Protect
the Best Interests of the Newborn

The criteria developed for newborn screening by advisory committees
within the United States are necessary to protect the best interests of the
child with regard to newborn screening. Wilson and Junger published the
first set of criteria addressing the issue of newborn screening in 1968.51
Their intention was to assist public health organizations and policy-makers
in determining how to bring treatment to those with previously undetected
diseases while avoiding harm to those persons not in need of treatment.52
By using these criteria, screening would occur only for disorders posing a
significant threat to the infant’s health where a treatment is available in the
event of a positive result.
As screening programs developed, different organizations released
their own criteria designed to help identify which disorders a screening panel
should include. In 1974, William K. Frankenburg53 addressed this issue and
concluded that:54
The availability of a suitable screening test does not justify
screening for a disease unless the disease is important,
47

See PAUL, supra note 24, at 176; Kolata, supra note 42.
See Levy & Albers, supra note 29, at 139.
49
D.A.C. Elliman, C. Dezateux & H.E. Bedford. Newborn and Childhood Screening Programmes:
Criteria, Evidence, and Current Policy, 87 ARCHIVES DISEASE CHILDHOOD 6 (2002).
50
See Therrell, supra note 19, at 67.
51
J.M.G. WILSON & G. JUNGER, Principles and Practice of Screening for Disease, in PUB. HEALTH
PAPERS No.34 (Geneva: World Health Organization 1968) [hereinafter WILSON & JUNGER].
52
See id. for the criteria developed by Wilson & Junger
53
William K. Frankenburg, MD, MSPH, is Professor Emeritus of Pediatrics and Preventative
Medicine at the University of Colorado School of Medicine.
54
William Frankenburg, Selection of Diseases and Tests in Pediatric Screening, 54 PEDIATRICS 612
(1974).
48
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relatively prevalent, and amenable to early treatment. . . .
Screening which is carried out without knowledge and
consideration of these criteria . . . may actually do more harm
than good.55
In 1975, the National Academy of Sciences also addressed the issue of
which disorders to include in newborn screening.56 Their criteria focused
more on the availability of treatment, including education, follow-up care,
and counseling, as well as the public benefit gained from the inclusion of a
test within the screening program.57 Another relevant change was the
addition of informed consent58 as a critical aspect of any screening done
upon a newborn.59
The Institute of Medicine published the next set of criteria in 1994.60
These focused on the benefit to the newborn rather than to the general
public, as well as the ability to confirm diagnosis and the availability of
treatment.61 The committee also noted that they did not believe “newborns
should be screened using multiplex testing for many disorders at one time
unless all of the disorders meet the principles described.”62
Finally, in 1999 the Maternal and Child Health Bureau (“MCHB”)63
responded to Congressional interest in newborn screening by providing
financial support for the American Academy of Pediatrics (“AAP”) to
convene a Newborn Screening Task Force.64 In 2000, this Task Force
published a report recommending the introduction of new tests in a
“carefully designed manner that facilitates evaluation of the risks and
benefits of screening, including the efficacy of follow-up and treatment
protocols.”65
55

Id.
See Therrell, supra note 19, at 68-69.
57
Id.
58
See Section V(D) for more information of the requirement of informed consent within the U.S.
59
Id.
60
For the criteria developed by the IOM see Committee on Assessing Genetic Risks, Institute of
Medicine, Assessing Genetic Risks: Implications for Health and Social Policy 5 (Lori B. Andrews et al.,
eds. 1994) [hereinafter IOM Report].
61
Id.
62
Id. at 5.
63
The U.S. Congress established the MCHB (originally the Children’s Bureau) in 1912. In 1935,
they enacted Title V of the Social Security Act, authorizing the MCHB services programs and providing a
foundation and structure for assuring the health of American mothers and children. This organization is a
bureau of the Health Resources and Services Administration under the U.S. Department of Health and
Human Services. See MCHB Home Page, http://mchb.hrsa.gov/about/default.htm (last visited Oct. 3,
2005).
64
See AAP, supra note 33.
65
Id.
56
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While the criteria in general have evolved throughout the years, no set
has emerged as the benchmark for all states to follow. As a result, there is a
vast disparity in the number of disorders screened among the states,66 and
children receive anywhere from four to thirty tests based solely upon where
they are born.67
While there is no one list of criteria that is universally followed
among the states, there are two criteria that resonate throughout. First, there
should be full understanding of the disorder to allow for accurate testing and
provide effective treatment for those found to have a positive test result.
Second, the test should offer a benefit to the newborn. Because these two
criteria permeate all the lists developed, one may conclude that every state
relied upon them to some degree when developing their screening panels.68
Today, the development of new technology capable of testing multiple
disorders from a single drop of blood is threatening the criteria upon which
these programs have relied. Testing with this technology allows healthcare
providers to identify more disorders; but these disorders do not necessarily
meet the criteria. A full understanding of the technology itself, including the
potential it provides for newborn screening, is necessary to grasp the legal
and political implications of this change.
III.

MS/MS THREATENS THE SCREENING CRITERIA DUE TO ITS POTENTIAL
TO SIGNIFICANTLY EXPAND THE SCREENING PANEL

MS/MS, one of the primary advances in technology influencing
newborn screening,69 has the potential to expand the screening panel by
testing for more disorders with just one drop of blood.70 This expansion
threatens the criteria used in the United States by encouraging expansion
prior to fulfillment of the criteria.
Scientists initially considered MS/MS for use in newborn screening
based on its ability to rapidly screen a single drop of blood for multiple
66

Id.
Because of this disparity, many now advocate for a federal policy mandating the number of
disorders included in newborn screening. See generally, McCabe et al., supra note 3.
68
Throughout the remainder of this comment, I will refer to these as the “two criteria” for including
a disorder on the screening panel.
69
Donald H. Chace, Thoedore A. Kalas & Edwin W. Naylor, Use of Tandem Mass Spectrometry for
Multianalyte Screening of Dried Blood Specimens from Newborns, 49 CLINICAL CHEMISTRY 1797, 1799
(2003) [hereinafter Chace et al.].
70
See, American College of Medical Genetics/American Society of Human Genetics Test and
Technology Transfer Committee Working Group, Tandem Mass Spectrometry in Newborn Screening, 2
GENETICS IS MEDICINE 267 (2000) [hereinafter ACMG/ASHG Working Group]; H. Hannon et al.,
Outcomes from Tandem Mass Spectrometry (MS/MS) Workshops in the United States and the Performance
Evaluation of MS/MS Laboratories, 34 SOUTHEAST ASIAN J. TROP. MED. & PUB. HEALTH 121, 121 (2003).
67
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disorders.71 The screening consists of analyzing the quantity of amino
acids72 and acylcarnitines73 present in the blood spot taken from the
newborn.74 In the case of inherited metabolic diseases, specific enzymes
that facilitate the breakdown of amino acids or the conversion of fat to
energy simply do not function.75 The compound accumulates in the blood
and tissue and becomes a poison to the child rather than a normal
substance.76 MS/MS measures these compounds in order to determine if too
much is present in the newborn’s blood, an indication of whether the child’s
metabolic system is functioning properly.77 If an abnormal amount is
present, the screeners can determine what particular disorder the child may
possess based upon which molecule is in excess.78 In this way, healthcare
workers use a single drop of blood to determine the health of a child with
regard to multiple disorders.
Advocates rationalize the use of MS/MS for newborn screening in a
number of ways. First, they point to the machine’s capability to screen for
thirty or more metabolic disorders from one drop of dried blood.79 In this
way, MS/MS significantly increases the potential of including more
disorders in newborn screening programs.80 For certain metabolic disorders
in which a treatment is known, early detection can result in a significant
improvement in the health of the child.81 Furthermore, advocates argue that
even if the treatment for a certain disorder is unknown, identification will
still benefit the patient and family.82 Parents gain peace of mind in knowing
the existence of the disorder and are better able to plan for the future.83

71

See AAP, supra note 33.
Donald H. Chace, A Layperson’s Guide to Tandem Mass Spectrometry in Newborn Screening, at
http://www.savebabies.org/NBS/msms-chace.php (last visited Oct. 31, 2005) (on file with Journal)
[hereinafter Layperson’s Guide] (amino acids are the “building blocks” of proteins).
73
Id. (acylcarnite exists when a carnitie, the “transportation system” for fats in and out the cell’s
mitochondria, is attached to a fat indicating that it is functioning properly).
74
W. Harry Hannon & Scott D. Grosse, Using Tandem Mass Spectrometry for Metabolic Disease
Screening Among Newborns: A Report of a Work Group, 50 MMWR 1 (2001).
75
See Chace, supra note 69.
76
See id.
77
See Hannon & Grosse, supra note 74.
78
See Chace, supra note 69.
79
See, e.g., Press Release, Mayo Clinic, Mayo Clinic Researcher Calls for Improved Newborn
Screening Minnesota Method Accurate, Cost-Effective (Feb. 21, 2005), available at
http://www.mayoclinic.org/news2005-rst/2683.html (last visited Oct. 3, 2005) (the doctor interviewed
pointed out that MS/MS is able to screen for “upwards of 40 … genetic diseases”).
80
Id.
81
See Hannon & Grosse, supra note 74, at 2.
82
Id.
83
See Ellen Wright Clayton, Genetic Testing in Children, 22 J. MED. & PHIL. 233, 238 (1997).
72
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Additionally, scientists argue analysis by MS/MS is more sensitive,84
specific, and reliable than previous methods of newborn screening.85 For
example, research has indicated that MS/MS has a false positive rate up to
ten-fold lower for PKU screening than the best method previously
available.86 This device has also proven to be very accurate in that it can
measure a very small amount of material for the presence of a single
compound with excellent precision.87 The performance rate for analysis is
another rationale for its adoption in newborn screening, as the test takes only
a matter of minutes from start to finish.88 For these reasons, proponents of
MS/MS argue that states should adopt it for use in their newborn screening
programs.89
While the above rationales present a compelling argument for
incorporation of MS/MS into newborn screening programs, their evaluation
is not possible without also considering the negative impact of such an
adoption. One aspect of the technology advanced in opposition to its use for
newborn screening is the cost.90 The instrument itself costs around $400,000
per machine, but this expense alone is far from the total necessary to
incorporate the technology into screening programs.91 States must also
consider the cost of counseling and treatment as they are also an integral part
of the programs. In addition, scientists suggest that the use of MS/MS could
increase the number of patients identified annually by fifty to one-hundred
percent.92 These children will require follow-up testing, which can lead to
expensive treatments and/or counseling for the affected family members.93
This in turn will require an increase in physicians, nutritionists, and genetic
counselors involved in newborn screening programs.94 Furthermore, while
the method of screening is itself simple, analyzing the results is not.95
84
Sensitivity of testing refers to the ability of a test to pick-up a set factor, such as the abundance of
a particular amino acid in the blood. Specificity refers to the ability of the test to accurately report what
amino acid it has detected.
85
See, e.g., AAP, supra note 37; V. Wiley et al., Newborn Screening – Is It Really That Simple?, 34
SOUTHEAST ASIAN J. TROP. MED. & PUB. HEALTH 107, 107 (2003) (MS/MS has shown a sensitivity of
95.9% and specificity of 99.8%).
86
See id.; see also ACMG/ASHG Working Group, supra note 70, at 267 (“MS/MS is more accurate
than most methods now in use for newborn screening and would thus provide more specific and sensitive
screening for [PKU]”).
87
See Layperson’s Guide, supra note 72.
88
See ACMG/ASHG Working Group, supra note 70, 267.
89
Id.
90
See Chace et al., supra note 69.
91
Id.
92
ACMG/ASHG Working Group, supra note 70, at 268.
93
See Hannon & Grosse, supra note 74, at 14.
94
Id.
95
See Layperson’s Guide, supra note 72.

148

PACIFIC RIM LAW & POLICY JOURNAL

VOL. 15 NO. 1

Accurate analysis of the data requires extensive training, which further adds
to the expense of its incorporation.96
In addition to cost, those who oppose adopting MS/MS for newborn
screening cite the lack of knowledge about the disorders themselves.97 For
example, the specificity of the technology may lead to identification of
carriers who will never become symptomatic due to differing degrees of
severity within the disorder itself.98 Full understanding of the disorder is
necessary in order to differentiate between those who will suffer from it and
those who merely carry the trait.99 This issue leads many to caution against
outright adoption of MS/MS into newborn screening programs until more
knowledge is available about the disorders themselves.100
Despite the above-mentioned drawbacks of incorporating MS/MS,
thirty-four states101 have already incorporated it into their newborn screening
programs.102 States rationalize this adoption by referring to the vast number
of disorders MS/MS can detect.103 In addition, advocacy groups have
exerted significant pressure on policy-makers to adopt this technology,104
undoubtedly affecting the incorporation of the technology in many states.105
Due to the pressure from such interest groups, many states are expanding
their panels to include disorders never before incorporated into newborn
screening.106
This technology and the resulting expansion of newborn screening is
changing the face of newborn screening in the United States and worldwide.
The increasing ability to detect disorders pushes the limits of already
established criteria.107 Questions remain as to whether the criteria should, or
must, change due to the adoption of MS/MS.
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See ACMG/ASHG Working Group, supra note 70, at 268.
See Wilcken et al., supra note 12, at 2304.
98
See Hannon & Grosse, supra note 74, at 14.
99
See Wilcken et al., supra note 12, at 2304.
100
See, e.g., supra note 74, at 14.
101
Three of these states — California, Oklahoma, and Missouri — have mandated the screening but it
is not yet implemented. NATIONAL NEWBORN SCREENING STATUS REPORT (Oct. 21, 2005), http://genes-rus.uthscsa.edu/nbsdisorders.pdf (last visited Oct. 1, 2005).
102
Id.
103
Chace et al., supra note 69.
104
See Wilcken et al., supra note 12, at 2309.
105
See id.
106
In 1998, state mandatory panels screened from 0 to 8 disorders, while today, some states screen
for more than 30, with North Dakota screening for a total of 38 disorders, 32 of which are screened using
MS/MS. This startling increase indicates the effect MS/MS technology has had on the screening panel. Id.
107
Brink, supra note 7 (Lainie Ross, Associate Professor of Pediatrics and Clinical Director of the
MacLean Center of Clinical Medical Ethics at the University of Chicago stated, “[w]e may be creating this
whole community of people who have a diagnosis, some of whom never get sick.”).
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In addressing these issues, the United States can look to Australia,
which expanded newborn screening through the use of MS/MS. A close
evaluation of the results of the screening within that country is helpful in
determining what, if any, steps the United States should take in this area.
IV.

AUSTRALIA’S USE OF MS/MS FOR NEWBORN SCREENING REVEALS
PROBLEMS IN SUCH APPLICATION OF THE TECHNOLOGY

An Australian study utilizing MS/MS for newborn screening sheds
light on the problems associated with using this technology. Specifically,
such screening will result in the false identification of those who will never
be affected by a particular disorder.108 In 1998, the New South Wales
newborn screening program became the first to use MS/MS.109 Over the
next four years, the state laboratory tested 362,000 newborns for thirty-one
inborn errors of metabolism using this technology.110 The screeners
compared these results to the previous rate of clinical diagnosis for four
preceding four-year periods.111 At the end of the four years, screening had
identified and diagnosed fifty-seven newborns — forty-eight through
screening and six through clinical diagnoses occurring at or before the time
the screening results were available.112 Seven other patients received
clinical diagnosis after the testing period.113 Two patients born to mothers
with a known risk who also had affected siblings declined screening.114
In comparing the results to the prior history of clinical diagnoses for
disorders within newborns, the researchers found that this screening
diagnosed two disorders at a significantly higher rate:115 medium-chain and
short-chain acyl-coenzyme A (“CoA”) dehydrogenase deficiency.116 While
there is no clear evidence whether identification of the short-chain variant
will be clinically useful,117 identification of the medium-chain variant
(“MCADD”) may prevent death among infants.
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See Wilcken et al., supra note 12, at 2309.
See Hannon & Grosse, supra note 74, at 33 (reporting on Bridget Wilcken & Veronica Wiley,
Tandem Mass Spectrometry in the New South Wales Newborn Screening Program for Metabolic Disease
Screening Among Newborns Workshop (June 2000)).
110
Wilcken et al., supra note 12, at 2308.
111
Id. at 2308.
112
Id. (the 6 that were identified clinically are also included in the 48 identified through the
screening).
113
Id. at 2309.
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Id. at 2309-10.
115
Id. at 2309.
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Id.
117
Id. at 2309-11.
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MCADD is a rare disease caused by the lack of an enzyme required to
convert fat to energy.118 Exposure of a child with MCADD to a period of
fasting can result in serious injuries or even death119 resulting from a buildup of fatty acids in the blood.120 Scientists estimate that the first episode of
fasting is fatal in thirty to fifty percent of patients.121 Treatment for this
disorder requires avoiding these periods of fasting.122
Following PKU, MCADD was the most commonly detected disorder
in the Australian study.123 The results of this study indicated the disorder has
a prevalence of approximately one in 19,000.124 However, many patients
identified by the screening as having the disorder remained healthy.125 This
absence of symptoms accounts for the significant difference between
children diagnosed through the MS/MS screening versus those diagnosed
clinically in the period prior to the study.126 The children who remained
undiagnosed under the previous model appear to have a different form of the
disease that either presents itself in a significantly milder fashion or perhaps
is completely benign.127 However, when MS/MS is used, there is no way to
differentiate these patients from those who are indeed at risk.128 For this
reason, physicians must treat all patients receiving a positive diagnosis as if
they are at risk, even though the child may develop symptoms.129 The
falsely identified children and their parents will be required to undergo
118
See Save the Babies Through Screening Foundation, Inc., Medium Chain Acyl-CoA
Dehydrogenase Deficiency (MCADDD), at http://www.savebabies.org/diseasedescriptions/mcadd.php (last
visited Oct. 4, 2005); Neil A. Holtzman, Expanded Newborn Screening – How Good is the Evidence, 290
JAMA 2606 (2003).
119
See Washington State Department of Health, Newborn Screening: Medium Chain Acy-coA
Dehydrogenase Deficiency (MCADD), available at http://www.doh.wa.gov/EHSPHL/PHL/Newborn
/mcadd.htm (last visited Oct. 4, 2005).
120
See Karl S. Roth, Medium-Chain Acyl-CoA Dehydrogenase Deficiency, in E-MEDICINE (Edward
Kaye et al., eds. 2003), available at http://www.emedicine.com/ped/topic1392.htm (last visited Oct. 4,
2005).
121
ACMG/ASHG Working Group, supra note 70, at 2671.
122
See Department of Public Health for the State of Connecticut, Genetics Newborn Screening
Program: MCADD Family Fact Sheet (Jan. 19, 2005), available at http://www.dph.state.ct.us/BCH/NBS/
Resources/mffs.pdf (last visited Oct. 4, 2005).
123
See Wilcken et al., supra note 12, at 2311; V. Wiley et al., Newborn Screening with Tandem Mass
Spectrometry: 12 Months’ Experience in NSW Australia, 88 ACTA PAEDIATRIC SUPPLEMENT 48 (1999).
124
See Kevin Carpenter et al., Evaluation of Newborn Screening for Medium Chain Acyl-CoA
Dehydrogenase Deficiency in 275,000 Babies, 85 ARCHIVE OF DISABLED CHILD FETAL NEONATAL
EDUCATION F105 (2001).
125
See Wilcken et al., supra note 12, at 2311.
126
Id.
127
Id.
128
BS Andresen, et al., The Molecular Basis of Medium-chain Acyl-CoA Dehydrogenase (MCADD)
Deficiency in Compound Heterozygous Patients: Is There Correlation Between Genotype and Phenotype, 6
HUMAN MOLECULAR GENETICS 695 (1997).
129
See Wilcken et al., supra note 12, at 2311.
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genetic counseling and a stringent management plan in order to prevent a
risk that was never a reality to the child.130 The Australian scientists
themselves acknowledged that “decisions on expansion of the newborn
screening programmes to include [MCADD] deficiency should be taken in
the knowledge that this is a complex disorder, and that not all cases
discovered by newborn screening may be at risk.”131
This overly-broad treatment due to insufficient knowledge of a
particular disorder is not a new development within newborn screening
programs — it was also present in the early days of PKU screening.132
While the researchers during that time eventually gained enough information
to lower the false-positive results, the interim period saw severe
consequences for many children falsely identified as diseased.133 The fact
that a different disorder is encountering similar problems indicates that states
should use caution before proceeding with such screening in order to avoid
this result for even more disorders.
Despite the issues surrounding diagnosis of children at risk for
MCADD, the New South Wales program successfully demonstrated that
MS/MS detects more cases of inborn errors of metabolism than clinical
diagnosis.134 Like MCADD, however, many of the other thirty-one
disorders included in the screening are complex and not yet fully
understood. Therefore, not all infants receiving positive results will actually
be at risk as some will never become symptomatic.135 Until scientists
conduct more studies of these disorders, this result is inevitable.136
V.

THE UNITED STATES SHOULD BE CAUTIOUS WHEN INCORPORATING
MORE DISORDERS INTO THEIR SCREENING PANELS

The results of the Australian study indicate that the United States, and
others considering the usage of MS/MS to expand newborn screening
panels, should proceed cautiously prior to incorporating new disorders into
their programs. In the United States, a direct comparison to the results of the
Australian study is possible due to a close resemblance between the newborn
screening programs of these two countries.

130
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133
134
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See Carpenter, supra note 124, at F105.
Id. at F108.
Clayton, supra note 20, at 106.
Id.
Wilcken et al., supra note 12, at 2304.
Carpenter et al., supra note 124, at F105.
Id.
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Similarities Between the Australian and the United States’ Newborn
Screening Programs Provide for Accurate Comparisons of the
Methods Used for Testing

The United States can learn from the results of the Australian study
due to similarities between the newborn screening programs in these two
countries. Like the United States, Australia first established newborn
screening programs in the late 1960s137 and implemented them through statewide programs around 1970.138 Australia consists of six states and two
territories,139 each of which is responsible for coordinating newborn
screening services through centralized state laboratories. 140 This resembles
the state-by-state approach currently in use in the United States. In addition,
the Australian program is fully publicly funded;141 much like its counterpart
in the United States where each state’s Department of Health provides most
of the funding.142 One final similarity is the method both countries use for
developing the screening panel. In Australia, a joint subcommittee of the
Human Genetics Society of Australia (“HGSA”) and the Division of
Paediatrics of the Royal Australasian College of Physicians (“RACP”)
generates policy statements recommending screening policies applicable to
all states and New Zealand.143 The individual states then use these
recommendations to determine the specifics of their program, including the
methods used and disorders included in the screening panel.144 In this way,
the HGSA Policy Statements serve a similar function to the criteria
developed by different advisory committees within the United States; they
offer guidance to lawmakers in structuring the newborn screening
programs.145 Overall, the similarities between these two programs allow
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See HGSA Policy Statement 2004, supra note 18.
Diane Webster, Newborn Screening in Australia and New Zealand, 34 SOUTHEAST ASIAN J. TROP.
MED. & PUB. HEALTH 69, 69 (2003).
139
The states are: New South Wales, Queensland, South Australia, Tasmania, Victoria, and Western
Australia; the territories are: Australian Capital Territory and Northern Territory. See Australian
Government: Department of Foreign Affairs and Trade, Australia: An Introduction, available at
http://www. dfat.gov.au/facts/intro.html (last visited Oct. 4, 2005).
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HGSA Policy Statement 2004, supra note 18.
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See Webster, supra note 138.
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Id.
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Id.
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Id.
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In the most recent HGSA Policy Statement (2004), the committee listed the following criteria as
factors that should be present for a disorder to be included within the newborn screening program: “(1)
there is a benefit for the baby from early diagnosis (benefit to the family may also benefit the baby); (2) the
benefit is reasonably balanced against financial and other costs; (3) there is a reliable test suitable for
newborn screening; (4) there is a satisfactory system in operation to deal with diagnostic testing,
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lawmakers in the United States to analyze the results of the Australian study
when assessing the development of the programs within their state.
B.

The Australian Study Demonstrates That Many of the Disorders
Proposed for Addition into Newborn Screening in the United States
Fail to Meet the Criteria Traditionally Relied Upon

When lawmakers in the United States assess their newborn screening
programs in conjunction with the Australian study utilizing MS/MS, they
will recognize that such technology is not appropriate for the screening of
many disorders due to the failure of such disorders to meet the necessary
criteria.146 In many states, however, this expansion has already occurred or
is in the process of occurring.147 For these states, the issue is whether
legislators need to make changes to the current programs in order to
accommodate this expansion. An evaluation of these disorders using the two
criteria discussed above indicates that care is necessary prior to their
incorporation into the screening panel.
Now that scientists know MS/MS detects more disorders than
previous screening methods,148 the question is whether these new disorders
meet the old criteria utilized by the states. 149 Closer evaluation reveals
problems in this regard. One may argue that since these disorders have not
previously been included in screening they must not meet the criteria.
However, scientists rationalize the expansion of screening to include these

counseling, treatment and follow-up of patients identified by the test.” Id.; HGSA Policy Statement 2004,
supra note 18.
146
See supra Part II(B).
147
See NATIONAL NEWBORN SCREENING STATUS REPORT (2005), supra note 101. Currently, only 11
states, including the District of Columbia, do not use this technology at all. It is mandated in 34 states (in 3
it has not yet been implemented), part of universal pilot programs in 4 states, and not mandated, but
available through pilot programs or by request, in 7 states. Overlap occurs because in some states testing is
mandated while in others it is available through pilot programs. For example, in New Jersey, 11 disorders
are mandated while 8 are not mandated but available through pilot programs or by request. New Jersey is
therefore included in both of these subgroups. Id.; see also P. Rinaldo, Recent Developments and New
Applications of Tandem Mass Spectrometry in Newborn Screening, 16 CURRENT OPINION PEDIATRICS 427,
427 (2004) (“newborn screening in the United States is undergoing a rapid expansion driven by the
introduction of tandem mass spectrometry in at least 34 state programs); Alissa Johnson, Newborn Genetic
and Metabolic Disease Screening, NATIONAL COUNCIL OF STATE LEGISLATURES (2005), available at
http://www.ncsl.org/programs/health/genetics/newborn.htm (last visited Oct. 4, 2005) (“[r]ecent advances
in technology have enabled some states to add a substantial number of conditions to the newborn screening
panel in a relatively short timeframe”).
148
See Wilcken et al., supra note 12, at 2304.
149
For a list of disorders proposed for screening through MS/MS, see HGSA Policy Statement 2004,
supra note 18, for Australia, and March of Dimes, Recommended Newborn Screening Tests: 29 Disorders,
at http://www.marchofdimes.com/professionals/681_15455.asp (last visited Oct. 31, 2005) [hereinafter
March of Dimes] for the U.S.
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disorders by the increased rate of detection. The implications of such a
change are apparent when evaluating one of these disorders in detail.
In the first Australian study on the usage of MS/MS for newborn
screening, the researchers concluded that the greatest increase in the rate of
diagnosis from the old system to the new one occurred with regard to
MCADD.150 A United States study in New England later reported similar
results.151 This disorder is consequently one of the primary rationales for
utilizing MS/MS in newborn screening. However, when compared against
the current criteria for adding a disorder to the screening panels within the
United States, it is clear that MCADD fails to meet the two required factors
— knowledge of the disorder and benefit to the child.152
First, scientists lack full understanding of this disorder. The
significant increase noted in the Australian study of children identified with
MCADD through MS/MS, versus those previously identified, indicates that
at least some of these children have different genotypes for the disorder than
those associated with severe health episodes or sudden death.153 This
increase is due to over-detection by the tandem mass spectrometer resulting
from a lack of knowledge on the different genotypes associated with the
disorder.154 Instead of detecting only the children at severe risk, the
screening picks up those with benign or mild forms of the disorder who will
never develop symptoms.155
More research is necessary to allow
differentiation between these two groups. Until the genotype associated
with the disorder is clearly understood, healthy children will continue to be
labeled as diseased – a diagnosis which could potentially affect many
aspects of their life.156 The criteria require full understanding of a disorder
prior to their incorporation in screening programs for precisely this reason.
150
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Second, there is no clear benefit to the child. The large number of
children identified from screening who developed no symptoms indicates
that the risk is not as high as was previously believed.157 In reality, not all
children with this genotype are at risk. Since they are not at risk, the testing
is not beneficial to them. MCADD therefore fails with regard to this
criterion.
Those advocating the use of MS/MS in newborn screening argue that
this technology will allow for detection of additional disorders from a single
screen.158 MCADD is one of the strongest examples in this regard due to the
fact research has shown MS/MS identifies more patients with this
disorder.159 However, the prior discussion demonstrates that such screening
presents new issues not encountered in the previous screening programs
based upon the failure of this disorder to meet the criteria currently used. If
MCADD presents the best results, the other disorders proposed for
adoption160 will also fail to fit within these criteria.
1.

Adapting Criteria to Incorporate More Disorders into Newborn
Screening Programs Is Incongruent with Legal Principles of the
United States

In light of differences in American legal principles, the United States
must differ from Australia in the method used to allow for inclusion of new
disorders within American states’ screening programs. Australia has
resolved the problems faced in the United States regarding the adoption of
these new disorders through a slight modification to their criteria, but a
similar change is not possible within the United States because of the
differences between the criteria utilized by the two countries. While the
United States requires full understanding of the disorder prior to
incorporation in a screening panel, the HGSA Policy Statement does not
include such a requirement.161 This absence avoids the issue encountered in
the United States arising from the requirement for full understanding of the
various genotypes of a disorder, such as MCADD, prior to adding it to the
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See Carpenter et al., supra note 124, at F1008 (“not all cases discovered by newborn screening
may be at risk.”).
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See Laypersons Guide, supra note 72.
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See Wilcken et al., supra note 12.
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Another example is 3-Methylcrotonyl-CoA carboxylase deficiency (“3MCC”), which is described
as a disorder that can lead to brain damage, seizures, liver failure and death, or may result in no symptoms
at all. Furthermore, while treatment may be helpful, a positive result on the screening test “could be related
to abnormal metabolites in the mother and not the baby.” March of Dimes, supra note 149.
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HGSA Policy Statement 2004, supra note 18.
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states’ screening panels. The Australian states have not had to address this
issue in adding MCADD, as well as other disorders, to its screening panels.
Additionally, Australian policy-makers have made slight but
significant adjustments to their criteria in order to allow incorporation of
such disorders into newborn screening. The first criterion in the 1999 HGSA
Policy Statement asserts that “newborn screening is recommended provided
that . . . [t]here is a benefit for the individual from early diagnosis.”162
However, by 2004, this requirement changed to state: “[t]here is benefit for
the baby from early diagnosis (benefit to the family may also benefit the
baby).”163 Rather than requiring a benefit to the child alone, Australia now
allows for the addition of a disorder if it offers benefit to the family.164 If the
benefit need not be to the child alone, this implies that the child also need
not be at risk, as is required in the United States. This change, however,
allows for the addition of almost any genetic disorder to the newborn
screening panel because the family of the child will likely benefit by
acquiring knowledge regarding their own genetic make-up. For example,
such knowledge can assist parents, and other relatives, in future decisions
regarding child-bearing. Therefore, it is apparent that Australia has greatly
expanded the scope of its newborn screening programs to incorporate
numerous new disorders based upon this single change in the criteria.
2.

The United States Must Either Change Its Criteria or Limit the Usage
of MS/MS

If the American states intend to continue using MS/MS for newborn
screening, there are two ways in which they can address the issue of new
disorders that fail to meet the current criteria. First, the states could choose
to keep the criteria and simply not allow incorporation of new disorders into
the screening panel until they meet all of the necessary criteria. Second, the
states may decide to change the criteria in order to incorporate these
disorders at the present time, as was done in Australia.
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HGSA Policy Statement 1999, supra note 16.
HGSA Policy Statement 2004, supra note 18 (emphasis added).
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In an e-mail received from Ms. Diane Webster, chairperson of the HGSA-RACP Newborn
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autosomal recessive disorder is known in a family they can make better informed reproductive choices and
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validly considered.” E-mail from Diane Webster, Chairperson of the Joint HGSA-RACP Newborn
Screening Committee, to Lauren Fisher, Law Student, University of Washington School of Law (Apr. 27,
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The second option is not viable for the United States. Australia
amended its criteria to allow for testing of a child so long as it offers benefit
to either the child or the child’s family. This enables testing of one
individual in order to benefit another. A similar change in the United States
is contrary to American values in that it violates the principle of personal
autonomy.165 Therefore, such an amendment would not be legally
acceptable in the United States.
The remaining option for the United States is to leave their system
unaltered, thereby choosing not to expand the screening panel until a
disorder fulfills the criteria. There are a number of problems associated with
this option. First, and perhaps most importantly, one of the primary
rationales for using MS/MS is its ability to screen for a large number of
disorders from a single drop of blood.166 Restricting such broad application
of MS/MS reduces the value of an expensive piece of medical equipment.
States must then decide whether to budget for MS/MS when previously used
screening methods can already test for the approved disorders. Only the
states themselves can make this determination through a cost-benefit
analysis.
The second issue raised is whether the states will be able to refrain
from adding disorders until they meet the criteria. Once this technology is in
place, pressure from advocacy groups may lead state policy-makers to
abandon the traditional criteria in order to add new disorders to the screening
panel. In the past, advocacy groups have played a significant role in the
expansion of newborn screening programs by lobbying for the inclusion of
more genetic disorders within the screening panel.167 In recent years, such
lobbying has proved effective, and there is a significant trend in the states to
increase the screening panel.168 Therefore, it is not only safe to assume that
the adoption of this technology will lead to an increase in the number of
disorders tested; it is nearly a proven fact.169 Even if states do not intend to
165

See Washington v. Glucksberg, 521 U.S. 702, 777 (1997) (Souter, J., concurring) (there is a
constitutionally protected liberty interest in bodily integrity and the right to determine what medical
treatment shall be accepted or refused).
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Cf. ACMG/ASHG Working Group, supra note 70, at 267.
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See Holtzman, supra note 118; see also March of Dimes, supra note 149; Save Babies Through
Screening Foundation Home Page, at http://www.savebabies.org (last visited Oct. 4, 2005) (Save the
Babies is an organization formed by parents of disabled children and an influential advocacy group that has
exerted pressure upon legislators to add more disorders to newborn screening).
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From 1998 to 2004, some U.S. states increased their screening panel from less than 5 to more than
30. This significant increase is due to the incorporation of MS/MS technology into these programs and
shows the impact advocacy groups have over the legislative process in this area. NATIONAL NEWBORN
SCREENING STATUS REPORT, supra note 101.
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For a complete list of all the disorders currently mandated by states for inclusion in the newborn
screening program, see id.
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expand the screening panel beyond those disorders meeting the criteria, such
expansion may be inevitable.170
Given that many states have already incorporated numerous new
disorders into their newborn screening panels, states should not mandate this
screening until the disorders meet the criteria previously required.171 For
many disorders, such as MCADD, this requirement would mean increasing
the knowledge of the disorder itself to raise the false-positive rate to an
acceptable level. Some states have implemented pilot programs to gain this
knowledge without mandating screening.172 However, this action also raises
legal issues policy-makers must address before moving forward with such
programs.
C.

The Informed Consent Requirements in the United States Restrict
Expansion of Newborn Screening Through MS/MS

The doctrine of informed consent further restricts expansion of
newborn screening. Traditionally, every disorder included within screening
caused a severe risk to the health of the child, as was required to meet the
criteria. A severe health risk created a compelling reason to require the
screening. However, by expanding the scope of the screening panel to
include disorders not posing as great a threat, the use of MS/MS reduces the
compelling nature of the need to screen.
Informed consent developed out of the 1946 Nuremberg Code173 and
has become one of the cornerstones of our healthcare system. This principle
requires healthcare providers to receive voluntary and fully informed
consent from a patient, or that patient’s representative, prior to performing
any treatment.174 Newborn screening programs, however, have accompanied
the emergence of an alternate method of consent different than full and
voluntary consent of the parent or guardian. While all states currently have
170
See William J. Rhead & Mira Irons, The Call from the Newborn Screening Laboratory:
Frustration in the Afternoon, 51 PEDIATRIC CLIN. NORTH AM. 803, 804 (2004) (observes that some
disorders have been added to newborn screening programs in the United States without researchers
knowing if there is a true benefit to early diagnosis and treatment, which is one of the criteria traditionally
used for including a disorder in the screening panel).
171
For states already mandating screening of disorders that do not meet the criteria, policy-makers
should at least discuss the implications of such policy and make adjustments they deem appropriate.
172
See NATIONAL NEWBORN SCREENING STATUS REPORT, supra note 101 (Florida, Louisiana,
Maryland, Massachusetts, Montana, Nebraska, New Jersey, Oregon, Pennsylvania, South Dakota, Texas
and Utah currently use pilot programs in their newborn screening programs).
173
See Risk and Vulnerable Groups, 4 ENCYCLOPEDIA OF BIOETHICS 2365, 2368 (3d ed., Stephen G.
Post ed., 2005) (“[t]he voluntary consent of a human subject is absolutely essential”).
174
See, e.g., Canterbury v. Spence, 464 F.2d 772, 780 (D.C. Cir 1972.) (“[t]rue consent to what
happens to one’s self is the informed exercise of a choice, and that entails an opportunity to evaluate
knowledgeably the options available and the risks attendant upon each.”)
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statutes requiring newborn screening,175 only Wyoming176 and Maryland177
require informed consent by the parents prior to screening.178 All others,
with the exception of South Dakota,179 have an “opt out” policy180 under
which parents must explicitly refuse screening in order to prevent it from
occurring.181 In the majority of states, parents must base this refusal upon
specific enumerated reasons, such as religion.182 However, many states deny
parents the opportunity to “opt out.”183 Research has indicated these states
rarely present parents with an opportunity to refuse testing.184 Instead,
healthcare workers inform the parents about the testing only after it has
occurred.185
The justification for allowing states to perform newborn screening
without the explicit informed consent of the parent is that parents do not
have the authority to forego effective treatment for their child when that
child has a life-threatening condition.186 Since all of the disorders
traditionally incorporated into the newborn screening panel were both lifethreatening and amenable to treatment, the compelling interest of protecting
the health of the child outweighed the infringement upon the fundamental
right of the parent.187 States now face the question of whether the current

175
Cynthia E. Fruchtman & Francis C.J. Pizzulli, Ethical Aspects of Genetic Testing, 20 WHITTIER L.
REV. 411, 415 (1998).
176
WYO. STAT. ANN. § 35-4-801(c) (1977) (“Informed consent of parents shall be obtained)
(emphasis added).
177
MD. CODE ANN., [Health] § 13-109(e)(2) (1982).
178
See AAP Policy Statement, supra note 23. See also, Elaine H. Hiller et al., Public Participation in
Medical Policy Making and the Status of Consumer Autonomy: The Example of Newborn Screening in the
United States, 87 AM. J. PUB. HEALTH 1280, 1283 (1997).
179
S.D. CODIFIED LAWS § 34-24-17 (1973).
180
For an example of legislation setting forth an “opt out” policy, see Washington’s applicable
legislation at WASH. REV. CODE § 70.83.020.
181
See American Academy of Pediatrics: Committee on Bioethics, Policy Statement: Ethical Issues
with Genetic Testing in Pediatrics, 107 PEDIATRICS 1451 (2001), available at
http://www.aap.org/policy/re9924.html (last visited Oct. 5, 2005) [hereinafter AAP Policy Statement].
182
See Katherine L. Acuff, Prenatal and Newborn Screening: State Legislative Approaches and
Current Practice Standard, in AIDS, WOMEN AND THE NEXT GENERATION – TOWARDS A MORALLY
ACCEPTABLE PUBLIC POLICY FOR HIV TESTING OF PREGNANT WOMEN AND NEWBORNS 121, 134-162
(Ruth R. Faden et al., eds., Oxford University Press 1991) (listing screening statutes and their applicable
opt out requirements).
183
See Fruchtman & Pizzulli, supra note 175, at 416.
184
Id.
185
See id.
186
See AAP Policy Statement, supra note 181; George C. Cunningham, Balancing the Individual’s
Right to Privacy Against the Need for Information to Protect and Advance Public Health, in GENETIC
SCREENING FROM NEWBORNS TO DNA TYPING 210 (Bartha Maria Knoppers & Claude M. Laberge eds.,
1990).
187
See, e.g., Parham v. J.R., 442 U.S. 584, 602 (1979) (parents have a constitutionally protected right
to obtain needed medical treatment for their child).
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“opt out” method should, or must, change as they begin using MS/MS to
screen newborns.
Australia serves as an example of how to implement informed consent
within these programs. Section 4.1 of the HGSA Policy Statement of 2004
states: “[p]arents should be informed of the availability of testing. If after
discussion the parents refuse to have their newborn tested, they should sign a
statement that they are fully informed about the test and the consequence of
not testing.”188 The committee amended this provision from the 1999
version which provided that “[t]he individual responsible should ensure that
parents are given information about the screening prior to the test being
taken.”189 This amendment indicates that Australia tightened its informed
consent requirements due to the incorporation of MS/MS into the programs.
Instead of a parent merely needing to receive information about the
screening, states now guarantee a full discussion regarding the screening
program’s affect on their child. The use of MS/MS has therefore led to a
more meaningful consent requirement in Australia.
In the United States, a similar change is necessary based on the
incorporation of this technology. While the current opt out policy was
justifiable with regard to the traditional disorders, the addition of new
disorders to the screening panel removes the compelling nature of the testing
for at least some of the disorders. Due to the current lack of understanding
surrounding these new disorders, physicians can no longer assume that the
children identified are in a life-threatening position. Therefore, the state
interest no longer outweighs the fundamental right of the parents, because it
lacks the compelling nature required. States should therefore mandate some
form of consent for this testing to satisfy the legal requirements of the
American healthcare system.190
For the United States, merely requiring informed consent does not
completely address the legal problems implicated by this new program. In
order to learn more about these disorders, screening must occur on a large
number of children to identify those affected. In fact, four states have
already incorporated universal pilot programs on all newborns. 191 Gaining
the requisite information regarding the disorders will depend upon such pilot
programs because otherwise, the sample population will not be large enough
188
189
190

HGSA Policy Statement 2004, supra note 18.
HGSA Policy Statement 1999, supra note 16.
See Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972); Truman v. Thomas, 611 P.2d 902 (Cal.

1980).
191
NATIONAL NEWBORN SCREENING STATUS REPORT, supra note 101 (the 4 states are Louisiana,
Maine, Massachusetts, and Oregon).
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to produce any viable results. Therefore, states will need to implement
universal pilot programs in order to identify subjects to study with the hope
of increasing knowledge of the disorder itself. These universal pilot
programs are more likely to be characterized as research programs rather
than medical procedures.
D.

Newborn Screening Pilot Programs May Potentially Be Classified As
Research Which Further Prevents Expansion of the Screening Panel

One final hurdle facing the expansion of the screening panel after
adoption of MS/MS is the possibility that such programs will be classified as
research. Increased understanding of many of the disorders proposed for
screening is required for the disorders to meet the criteria utilized by the
states’ lawmakers. Because they are so rare, scientists cannot effectively
study these disorders unless screening occurs on an extremely large number
of individuals.192 For this reason, many advocates of the technology have
recommended implementing universal pilot programs193 in order to utilize
the technology to identify affected children, thus allowing further study on
the disorder itself.194 As was previously mentioned, four states currently
practice universal screening195 on all babies under pilot programs designed
to study these rare disorders.196 Such programs raise the issue of whether
policy-makers should require specific informed consent from parents for this
type of testing and whether the consent of the parent is sufficient.
The United States’ scientific community defines research as “a
systematic investigation, including research development, testing and
evaluation, designed to develop or contribute to generalizable
knowledge.”197 Universal pilot programs potentially meet this definition. In
the United States, however, there is a separate set of requirements for
192
The incidence rates of some of these disorders are: Citrullinemia – less than 1 in 100,000,
Argininosuccinic academia – less than 1 in 100,000, Tyrosinemia type I – less than 1 in 100,000, Maple
syrup urine disease – less than 1 in 100,000, isovaleric academia – less than 1 in 100,000. See March of
Dimes, supra note 149.
193
Australia also recommends such pilot programs. Section 5.2 of the 2004 HGSA Policy Statement
provides that “[p]ilot studies should be undertaken to demonstrate the safety, effectiveness, validity and
clinical utility of tests for additional disorders and new testing technologies.” See HGSA Policy Statement
2004, supra note 18.
194
See, e.g., HGSA Policy Statement 2004, supra note 18, at 3 (“Pilot studies should be undertaken
to demonstrate the safety, effectiveness, validity and clinical utility of tests for additional disorders and new
testing technologies.”).
195
I have used the term “universal pilot program” to refer to a pilot program testing the entire
population of newborns within a state, thus making it universal.
196
See National Newborn Screening Report, supra note 191.
197
45 C.F.R. § 46.102(d) (1991).
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research programs,198 and any research performed using federal funds,199 or
otherwise subject to federal regulation, must comply with 45 C.F.R. § 46.200
Section 46.117 of this regulation addresses the issue of informed consent and
requires every research subject to give fully informed and voluntary consent
to the procedure prior to testing.201 However, the regulations provide
additional protections for research with children.202 If research poses only a
minimal risk203 or offers direct benefit to the child, the consent of only one
parent is required.204 Otherwise, the research requires the consent of both
parents, unless the child has only one parent or legal guardian.205 Under
either situation, the informed consent of at least one parent is required prior
to testing.
E.

Allowing Parents to Consent on Behalf of Their Children for
Expanded Newborn Screening Does Not Satisfy the Informed Consent
Requirements of the United States

The heightened requirements for research on children within the
United States prevents parents from being required to consent before
screening of disorders such as MCADD. Despite the allowance for testing
with parental consent under 45 C.F.R. § 46, the Maryland case of Grimes v.
Kennedy Krieger Institute, Inc.206 provides a strong argument against
allowing a requirement for such consent in the current situation. This case
held that parents cannot legally consent to the participation of their children
in non-therapeutic research (research posing no potential benefit to the

198
See Angela R. Holder, Physician’s Failure to Obtain Informed Consent to Innovative Practice or
Medical Research, 15 AM. JUR. PROOF OF FACTS 2d 711 § 3 (2005) (“After Nuremberg, and particularly in
the early 1970’s, public outcry over obvious abuses of research subjects, some of whom did not even know
that they were research subjects, led to several congressional investigations and consequent strict
regulation, particularly as to the informed consent of the research subject in all federally-funded research
activities, or those carried out in federal institutions.”).
199
Federal funds provide primary funding for newborn screening programs in the U.S., thus placing
these programs under the provisions of 45 C.F.R. § 46 (1991).
200
45 C.F.R. § 46.101 (1991).
201
45 C.F.R. § 46.116 (1991) (general requirements for informed consent state that “[e]xcept as
provided elsewhere in this policy, no investigator may involve a human being as a subject in research
covered by this policy unless the investigator has obtained the legally effective informed consent of the
subject or the subject’s legally authorized representative…”).
202
45 C.F.R. § 46, Subpart D (1991).
203
“’Minimal risk’ means that the probability and magnitude of harm or discomfort anticipated in the
research are not greater in and of themselves than those ordinarily encountered in daily life or during the
performance of routine physical or psychological examinations or tests.” 45 C.F.R. 46.102(i).
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45 C.F.R. § 46.408(b).
205
Id.
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782 A.2d 807 (Md. 2001).
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child).207 The court stated that a parent “cannot consent to the participation
of a child … in non-therapeutic research or studies in which there is any risk
of injury or damage to the health of the subject.”208 In reaching this
decision, the Grimes court relied upon a decision from the New York Court
of Appeals.209 In T.D. v. New York Office of Mental Health,210 the Appellate
Court determined that provisions in the regulations authorizing parents to
consent on behalf of children for participation in non-therapeutic research
posing greater than minimal risk to the child were insufficient.211 The
Grimes court concurred with this conclusion in reaching its own holding.
The decision in Grimes “sent shockwaves through the public health research
community” due to its potential impact upon pediatric research.212 This
impact clearly affects newborn screening, and state lawmakers should
consider this legal precedent when deciding whether to utilize pilot
programs in this area.
Based upon the Grimes holding, treatment for each disorder proposed
for addition into the newborn screening panel through pilot programs should
first be required to offer a therapeutic benefit to the child. Policy-makers
should use a case-by-case analysis in making this determination. If no
therapeutic benefit is present, then testing may not involve a potential risk to
the child as is required for incorporation of the disorder into screening.
The pilot programs that states are using to study new disorders may be
characterized as non-therapeutic research upon the child. These programs
provide no significant potential benefit to the child due to the rarity of the
disorders and the lack of knowledge on the disorder itself. Policy-makers
cannot realistically view these disorders as providing a viable potential
benefit to the child because they are incredibly rare.213 Furthermore, even if
a child receives a positive result, MCADD has shown there may continue to
be no benefit to that child because it is unknown whether they will ever
become symptomatic. Therefore, it is a stretch to say that a child is
207
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receiving a benefit from the addition of these disorders onto the screening
panel due to the odds of that particular child actually receiving any type of
benefit.
Under the Grimes ruling, since these programs offer no therapeutic
benefit to the child, if they pose any risk to the child’s health the consent of
the parent is insufficient. The risk of discrimination, as well as potential
physical and mental health problems resulting from the screening, are
sufficient to negate the consent of the parent to this screening.
The risks presented to the physical health of the newborn from
receiving this screening range from minimal to life-threatening. As was
indicated through the hasty adoption of universal PKU screening, the
treatment given to children with false positive test results can be severely
debilitating, if not fatal.214 The presence of this risk alone is sufficient to
conclude that this screening does not satisfy the Grimes standard.
The potential negative impact of treatment, however, is not the only
risk associated with such screening. A positive test result can adversely
affect the parent-child relationship by interrupting the first days of the
newborn’s life when bonding is the most important.215 In this way, screening
poses a risk to the mental health of the children involved.
Another risk that arises is the potential for discrimination.216 In the
early stages of any screening program, mislabeling will undoubtedly
occur.217 Research has suggested that a positive test result can negatively
affect the mental health of the child due to loss of self-esteem from being
labeled as “diseased.”218 Children labeled as “diseased” forever carry the
burden of such a designation, even if they never present symptoms. This
labeling can result in discrimination against the child, and perhaps even
against the family. In 1998, studies indicated that there had been
approximately 200 documented cases of discrimination by insurance
companies against healthy individuals based upon the presence of a genetic

214
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characteristic or trait revealed through genetic testing.219 Falsely labeled
children are therefore at potential risk of never qualifying for adequate
health insurance based upon a test given to them when they were just a few
days old. Families may also suffer a similar fate, as parents may be unable
to obtain health insurance for their families based upon the knowledge of a
genetic disorder within the family genome.220
These potential risks, along with available legal precedent on parental
consent to research, lead to the conclusion that policy-makers cannot easily
solve the issues surrounding informed consent for the use of MS/MS in
newborn screening. Unlike Australia, simply requiring parents to provide
such consent will not eliminate the potential legal problems implicated by
such screening within the United States. The issues surrounding informed
consent should therefore serve to restrict the use of this technology to
disorders fitting within the two criteria. States should not include a disorder
until it can fulfill these criteria, and screening of the child should not occur
merely for the purpose of increasing knowledge of a particular disorder. The
fact that screening newborns is easier for the researchers due to the large
pool of subjects available does not justify overstepping the rights of even a
single child.
F.

Even If These Programs Are Classified As “Program Evaluation”
Instead of Research, They Continue to Require Meaningful Consent
from the Parents

One final alternative for policy-makers is to justify MS/MS newborn
screening as “program evaluation.” The Center for Disease Control
(“CDC”) has defined “program” to include any organized action such as a
research project221 and “evaluation” as the systematic application of
scientific methods to assess the design, implementation, improvement or
outcomes of a program.222 These evaluations are conducted in order to
discern whether programs should be “continued, improved, expanded, or
curtailed [and] to assess the utility of new programs and initiatives.”223 The
CDC temporarily excuses programs fitting within this definition from the
requirements of 45 C.F.R. 46. Despite qualifying as research, the use of
219
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MS/MS in newborn screening may be justified under this category. If this is
the case, policy-makers may find that the research is acceptable despite its
failure to satisfy the legal precedent’s requirements for research upon
children.
Even if these programs are justified under the definition of “program
evaluation,” there continues to be a need to at least require meaningful
informed consent from the parent or guardian of the child screened. While
parental consent is not sufficient if the program is viewed as research,224 this
specialized categorization of research does not justify returning to the “opt
out” policy currently in use.225 Again, many of the disorders added to the
screening panel do not fulfill the criteria for screening and therefore do not
present a compelling rationale to deprive the fundamental rights of the
parents. Therefore, even if policy-makers categorize the use of MS/MS for
newborn screening as “program evaluation,” they should at the least amend
the informed consent policies to require more meaningful consent of the
parents.
VI.

CONCLUSION

Overall, while many states are already utilizing MS/MS to screen for
up to thirty-two inborn errors of metabolism,226 this analysis indicates that
more caution is necessary in the future before continuing down this path.
The capability of the technology should not outweigh reason when
incorporating new disorders into screening programs. While the adoption of
MS/MS into the Australian newborn screening programs was successful,
differences in the informed consent of the United States requirements
prevent it from following an identical path. State policy-makers must
address informed consent and should amend the current policy to require
more meaningful consent from the parent or guardian. These policy-makers
should also consider how to address the criteria designed to give guidance
when incorporating new disorders into the screening panel. If they choose to
continue to rely upon these criteria, these policy-makers should use care not
to expand screening for disorders failing to fulfill these criteria. Both of
these recommendations will require caution by the states. Only by using
caution can the United States avoid the problems experienced in the early
days of PKU screening. Policy-makers should therefore use care to ensure
224
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that the disorders included within their states’ screening panel are
sufficiently understood to prevent a similar result. The rights of the newborn
child must remain at the forefront throughout all of these discussions. Such
consideration will limit screening to situations where the test is beneficial to
the child. In this way, technology can exist harmoniously with the deeplyrooted principles of the American legal system.

